Advancing Targeted
Therapies. Addressing
Significant Unmet Need.
Monopar:
A Biopharmaceutical Company
Monopar Therapeutics is a clinical-stage biotechnology company advancing next generation targeted therapies for Wilson disease, a rare genetic disorder, and for cancer.
At Monopar, we are focused on developing novel therapies to bring innovation to areas of significant unmet need. We have a passion for advancing therapies that improve patients’ lives.
STAY INFORMED
receive company updates straight to your inbox.
Pipeline
Monopar's pipeline includes ALXN1840, a late-stage asset with a rolling NDA submission in progress, for the treatment of Wilson Disease, as well as a number of personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers. Monopar builds its drug development pipeline through in-house efforts and licensing of late preclinical and clinical-stage therapeutics, leveraging its scientific and clinical expertise to reduce risk and accelerate development.
Therapeutic Areas of Focus
Rare Disease
Wilson disease (WD) is a rare, serious and progressive genetic condition that affects approximately one in 30,000 people, or 11,400 people in the US. It is a heterogeneous, autosomal recessive disorder caused by pathogenic variants in the ATP7B gene, resulting in impaired biliary copper (Cu) excretion and impaired incorporation of Cu into ceruloplasmin, leading to progressive accumulation of Cu in the liver and brain. If untreated or inadequately treated, Cu accumulation results in hepatic, neurologic, and psychiatric symptoms, and may lead to premature death.
Oncology
Approximately one in every two individuals will develop cancer during their lifetime. Cancer is one of the leading causes of death worldwide and the second leading cause of death in the United States and Europe, accounting for nearly 1 in 4 deaths in the US. Just as no two people are the same, no two cancers are the same. We believe the future of cancer treatment will be personalized and precise. We see the emerging field of radiopharmaceuticals as transforming cancer care through its personalized and precise approach to treatment.